cAMP responsive element modulator α promotes effector T cells in systemic autoimmune diseases

Immunology. 2023 Dec;170(4):470-482. doi: 10.1111/imm.13680. Epub 2023 Jul 12.

Abstract

T lymphocytes play a crucial role in adaptive immunity. Dysregulation of T cell-derived inflammatory cytokine expression and loss of self-tolerance promote inflammation and tissue damage in several autoimmune/inflammatory diseases, including systemic lupus erythematosus (SLE) and psoriasis. The transcription factor cAMP responsive element modulator α (CREMα) plays a key role in the regulation of T cell homeostasis. Increased expression of CREMα is a hallmark of the T cell-mediated inflammatory diseases SLE and psoriasis. Notably, CREMα regulates the expression of effector molecules through trans-regulation and/or the co-recruitment of epigenetic modifiers, including DNA methyltransferases (DNMT3a), histone-methyltransferases (G9a) and histone acetyltransferases (p300). Thus, CREMα may be used as a biomarker for disease activity and/or target for future targeted therapeutic interventions.

Keywords: CREM; epigenetics; lymphocyte; psoriasis; psoriatic arthritis; systemic lupus erythematosus.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases* / metabolism
  • Cyclic AMP Response Element Modulator / genetics
  • Cyclic AMP Response Element Modulator / metabolism
  • Humans
  • Lupus Erythematosus, Systemic*
  • Methyltransferases / metabolism
  • Psoriasis* / metabolism
  • T-Lymphocytes / metabolism

Substances

  • Cyclic AMP Response Element Modulator
  • Methyltransferases